Overview
Raltitrexed is a quinazoline-based antifolate drug developed as a chemotherapeutic agent. It was first approved in Europe in 1996 under the brand name Tomudex for advanced colorectal cancer. Unlike traditional 5-fluorouracil (5-FU) regimens, raltitrexed offers a simplified administration protocol with fewer side effects. As a selective thymidylate synthase (TS) inhibitor, it blocks the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), thereby impeding DNA synthesis. This mechanism makes it particularly effective against rapidly dividing cancer cells.
Physical and Chemical Properties
Raltitrexed is a white crystalline powder with moderate stability under recommended storage conditions. Its molecular structure features a quinazoline ring linked to a thiophene carboxylate group, contributing to its selective binding to thymidylate synthase. The drug exhibits pH-dependent solubility, with optimal stability in slightly acidic to neutral conditions (pH 5-7). Degradation occurs under strong light or high humidity, necessitating protective packaging. Analytical methods for purity testing typically involve HPLC with UV detection at 254 nm.
Main Applications
The primary clinical use of raltitrexed is in palliative treatment of metastatic colorectal cancer, either as monotherapy or in combination with oxaliplatin. It demonstrates comparable efficacy to 5-FU/leucovorin regimens but with reduced hematologic toxicity. Ongoing research explores its potential in malignant pleural mesothelioma and other TS-overexpressing tumors. Off-label applications include hepatocellular carcinoma and gastric cancer, though these require further clinical validation. The drug is typically administered intravenously every 3 weeks at 3mg/m² doses.
Safety and Storage
As a cytotoxic agent, raltitrexed requires strict handling protocols. Preparation should occur in a biosafety cabinet with nitrile gloves, goggles, and protective gowns. Accidental exposure requires immediate washing with copious water. Storage mandates refrigeration (2-8°C) in original vials with desiccants. Reconstituted solutions are stable for 24 hours at room temperature or 48 hours refrigerated. Monitoring parameters include complete blood counts, liver enzymes, and renal function due to risks of myelosuppression and hepatotoxicity.
B2B Procurement Guide
Pharmaceutical buyers should prioritize suppliers with WHO-GMP or EU-GMP certification. Batch-specific Certificate of Analysis (CoA) must include HPLC purity (>98%), residual solvent levels, and bacterial endotoxin testing. Bulk procurement (100+ vials) commonly attracts 15-30% discounts. Consider cold chain logistics partners with temperature monitoring for international shipments. Emerging markets may offer competitive pricing but require stringent quality verification. Alternative sourcing options include pre-filled syringes for clinical convenience.